A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1

Active, not recruiting

• Conditions: Advanced Solid Tumors Cancer
• Interventions: Drug: Nivolumab; Drug: Telisotuzumab vedotin; Drug: Osimertinib; Drug: Erlotinib

• Registration Number: NCT02099058
• Lead Sponsor: AbbVie

Brief Summary

This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01-15
• Study First Submitted: 2014-03-26
• Study First Submitted QC: 2014-03-26
• Study First Posted: 2014-03-28
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-25
• Last Update Posted: 2025-02-26
• Primary Completion: 2025-11
• Study Completion: 2025-11

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 237

Inclusion Criteria

• Participant must have advanced Non-Small Cell Lung Cancer (NSCLC) that is not amenable to surgical resection or other approved therapeutic options that have demonstrated clinical benefit.

• Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. For Monotherapy Expansion Cohort, participant must have ECOG Performance Status of 0 or 1.

• Participant must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

• Participant has archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue confirmed available for analyses.

• Participant has adequate bone marrow, renal, and hepatic function.

• Women of childbearing potential must have a negative serum pregnancy test at baseline.

• Participants in the combination therapy arms A and D must be eligible to receive erlotinib, or nivolumab per most locally approved labeling, or at the discretion of the Investigator.

• Participants in the combination therapy Arm E must satisfy following criteria.

  • Participant must have metastatic/locally advanced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R, with or without T790M mutation, and none of the EGFR mutations known to be resistant to osimertinib.
  • Participant must have received at least 1 but no more than 2 prior regimens, one of which must have contained osimertinib. Participant must have had disease progression while on osimertinib. Only 1 prior regimen may have contained chemotherapy. Consecutive EGFR TKIs will count as 1 regimen
  • Participant must have available post-progression tumor tissue for central c-Met immunohistochemistry (IHC) testing.
  • Participant has adequate bone marrow function.

• Participants in the Monotherapy Expansion Cohort must satisfy following criteria.

  • Participant must have locally advanced or metastatic, non-squamous, EGFR wild type, c-Met+ NSCLC. Participants must not have adenosquamous histology.
  • Participant must have received no more than 2 lines of prior systemic therapy (including no more than 1 line of systemic cytotoxic chemotherapy) in the locally advanced or metastatic setting.
  • Participant must have progressed on systemic cytotoxic chemotherapy (or are ineligible for systemic cytotoxic chemotherapy) and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible for an immune checkpoint inhibitor), and prior anti-cancer therapies targeting driver gene alterations (if applicable).
  • Participant should not have received prior c-Met-targeted antibody-based therapies.

Exclusion Criteria

• Participant has received radiation therapy to the lung < 6 months prior to the first dose of ABBV-399.

• Participant has received anticancer therapy including chemotherapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399.

• Participant has uncontrolled metastases to the central nervous system (CNS) based on head CT or MRI. Participants with brain metastases may be eligible 2-4 weeks after definitive therapy to all known sites of CNS disease provided they are asymptomatic and either off or on a non-increasing dose (in last 2 weeks) of systemic steroids and not on anticonvulsants for seizure activity directly related to progressive CNS metastases.

• Participant has history of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids.

• Participant has evidence of pulmonary fibrosis on screening imaging assessment or any history of pneumonitis or interstitial lung disease (ILD) within 3 months of the planned first dose of the study drug.

• Participant has unresolved clinically significant adverse events >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.

• Participant has had major surgery within 21 days prior to the first dose of ABBV-399.

• Participant has a clinically significant condition(s) described in the protocol.

• History of major immunologic reaction to any Immunoglobulin G (IgG) containing agent.

• Participant has any medical condition which in the opinion of the Investigator or Medical Monitor places the participant at an unacceptably high risk for toxicities.

• Participant is a lactating or pregnant female.

• Participant with known active COVID-19 infection, subjects with signs/symptoms associated with COVID-19 infection or known exposure to a confirmed case of COVID-19 infection during 14 days prior to Screening must be screen failed and may only rescreen after they have recovered from COVID-19 and they are no longer considered contagious, per investigator assessment.

• Participants enrolled on the combination therapy phase must satisfy the above exclusion criteria and also the following:

  • Participants may not receive ABBV-399 in combination with osimertinib, erlotinib or nivolumab if they have any medical condition which in the opinion of the Investigator places the participant at an unacceptably high risk for toxicities from the combination.

  • Participants may not receive nivolumab if they have:

    • Active autoimmune disease with exceptions of vitiligo, type I diabetes mellitus, hypothyroidism and psoriasis.
    • Used systemic corticosteroids (> 10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of study drug administration, with exception of inhaled, locally injected or topical steroids.
    • Known immunosuppressive disease, for example human immunodeficiency virus infection or history of bone marrow transplant or chronic lymphocytic leukemia.

  • Participants may not be enrolled into the osimertinib Combination Therapy Arm E if they have the following:

    • History of hypersensitivity to active or inactive excipients of osimertinib.
    • History of osimertinib dose reduction.
    • Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of osimertinib.
    • Any of the following cardiac criteria: a) Mean resting corrected QT interval (QTc) > 470 ms; b) Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG, e.g., complete left bundle branch block, second- or third-degree heart block, PR interval > 250 ms; c) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, or any concomitant medication known to prolong the QT interval.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Arm A (Telisotuzumab vedotin plus Erlotinib)	Erlotinib	Telisotuzumab vedotin to be evaluated with Erlotinib.
Arm D (Telisotuzumab vedotin plus Nivolumab)	Nivolumab	Telisotuzumab vedotin to be evaluated with Nivolumab.
Monotherapy Expansion Cohort	Telisotuzumab vedotin	Telisotuzumab vedotin will be administered every 14 days on a 28-day dosing cycle.
Arm D (Telisotuzumab vedotin plus Nivolumab)	Telisotuzumab vedotin	Telisotuzumab vedotin to be evaluated with Nivolumab.
Arm E (Telisotuzumab vedotin plus Osimertinib)	Osimertinib	Telisotuzumab vedotin to be evaluated with Osimertinib.
Arm E (Telisotuzumab vedotin plus Osimertinib)	Telisotuzumab vedotin	Telisotuzumab vedotin to be evaluated with Osimertinib.
Monotherapy Telisotuzumab vedotin (21-day dosing cycles)	Telisotuzumab vedotin	Telisotuzumab vedotin will be administered at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
Monotherapy Telisotuzumab vedotin(28-day dosing cycles)	Telisotuzumab vedotin	Telisotuzumab vedotin will be administered at escalating dose levels in 28-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate Telisotuzumab vedotin.
Arm A (Telisotuzumab vedotin plus Erlotinib)	Telisotuzumab vedotin	Telisotuzumab vedotin to be evaluated with Erlotinib.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events	Up to 24 Months	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or Nivolumab	Up to 24 Months	The RPTD of ABBV-399 when administered as monotherapy and in combination with osimertinib, erlotinib or nivolumab will be determined during the dose escalation phase of the study. RPTD will be determined using available safety and pharmacokinetics data.
Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)	Up to 24 months	AUC (0-t) = Area under the serum concentration versus time curve from time zero (pre-dose) to the time of the last measurable concentration.
Maximum observed plasma concentration (Cmax)	Up to 24 months	Maximum observed plasma concentration (Cmax).
Terminal elimination half life	Up to 24 months	Terminal elimination half life.
Time to Cmax (Tmax)	Up to 24 months	Time to Cmax (Tmax).

Trial Locations

Locations (36)

Washington University-School of Medicine /ID# 143798; 🇺🇸 Saint Louis, Missouri, United States

Summit Medical Group-Florham Park /ID# 217651; 🇺🇸 Florham Park, New Jersey, United States

Montefiore Medical Park at Eastchester /ID# 218445; 🇺🇸 Bronx, New York, United States

Northwell Health - Monter Cancer Center /ID# 218170; 🇺🇸 Lake Success, New York, United States

Duke Cancer Center /ID# 123763; 🇺🇸 Durham, North Carolina, United States

Tennessee Oncology, PLLC /ID# 129802; 🇺🇸 Nashville, Tennessee, United States

Mary Crowley Cancer Research /ID# 123760; 🇺🇸 Dallas, Texas, United States

University of Texas MD Anderson Cancer Center /ID# 154648; 🇺🇸 Houston, Texas, United States

Virginia Cancer Specialists - Fairfax /ID# 165708; 🇺🇸 Fairfax, Virginia, United States

Universitair Ziekenhuis Antwerpen /ID# 170118; 🇧🇪 Edegem, Antwerpen, Belgium

Duplicate_Tampere University Hospital /ID# 165065; 🇫🇮 Tampere, Pirkanmaa, Finland

AP-HM - Hopital de la Timone /ID# 151570; 🇫🇷 Marseille CEDEX 05, Bouches-du-Rhone, France

Institut Gustave Roussy /ID# 132747; 🇫🇷 Villejuif Cedex, Val-de-Marne, France

Duplicate_Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS /ID# 164077; 🇮🇹 Meldola, Emilia-Romagna, Italy

National Cancer Center Hospital East /ID# 217570; 🇯🇵 Kashiwa-shi, Chiba, Japan

National Cancer Center Hospital /ID# 217571; 🇯🇵 Chuo-ku, Tokyo, Japan

Duplicate_The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378; 🇰🇷 Suwon, Gyeonggido, Korea, Republic of

Asan Medical Center /ID# 217334; 🇰🇷 Seoul, Seoul Teugbyeolsi, Korea, Republic of

Yonsei University Health System Severance Hospital /ID# 217333; 🇰🇷 Seoul, Korea, Republic of

Radboud Universitair Medisch Centrum /ID# 246908; 🇳🇱 Nijmegen, Gelderland, Netherlands

National Taiwan University Hospital /ID# 167173; 🇨🇳 Taipei City, Taipei, Taiwan

China Medical University Hospital /ID# 217494; 🇨🇳 Taichung, Taiwan

National Cheng Kung University Hospital /ID# 167175; 🇨🇳 Tainan, Taiwan

Taipei Veterans General Hosp /ID# 217392; 🇨🇳 Taipei, Taiwan

Herbert Herman Cancer Center /ID# 149858; 🇺🇸 Lansing, Michigan, United States

Scottsdale Healthcare /ID# 123761; 🇺🇸 Scottsdale, Arizona, United States

City of Hope /ID# 153759; 🇺🇸 Duarte, California, United States

University of California, Los Angeles /ID# 148295; 🇺🇸 Los Angeles, California, United States

UC Irvine /ID# 165107; 🇺🇸 Orange, California, United States

University of California, Davis Comprehensive Cancer Center /ID# 129805; 🇺🇸 Sacramento, California, United States

Univ of Colorado Cancer Center /ID# 123759; 🇺🇸 Aurora, Colorado, United States

The University of Chicago Medical Center /ID# 136995; 🇺🇸 Chicago, Illinois, United States

Ingalls Memorial Hosp /ID# 165876; 🇺🇸 Harvey, Illinois, United States

Massachusetts General Hospital /ID# 129804; 🇺🇸 Boston, Massachusetts, United States

Dana-Farber Cancer Institute /ID# 168782; 🇺🇸 Boston, Massachusetts, United States

Duplicate_Henry Ford Health System /ID# 149857; 🇺🇸 Detroit, Michigan, United States